# US 2010/0168020 A1 · Stabilized receptor polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168020 A1
- Document ID: US20100168020A1
- Status: Published application
- Kind: A1
- Application number: 12/626,375
- Filed: 2009-11-25
- Published: 2010-07-01
- Earliest claimed: 2008-11-26
- Assignees: Amgen Inc.
- Inventors: Jeonghoon Sun; Lei-Ting Tony Tam; Mark Leo Michaels; Thomas C. Boone; Rohini Deshpande; Yue-Sheng Li; Hq Han
- Web page: https://patentgrep.com/patent/US20100168020A1

## CPC

- C07K 14/71: for growth factors; for growth regulators
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/26: Androgens
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/08: Bronchodilators
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/495: Transforming growth factor [TGF]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

## Claims

### Claim 1

An isolated protein comprising a stabilized activin IIB receptor polypeptide (svActRIIB) wherein said polypeptide is selected from the group consisting of:
(a) a polypeptide consisting of the sequence set forth in SEQ ID NO: 2, except for a single amino acid substitution at position 28, and a single amino acid substitution at position 44, wherein the substitution at position 28 is selected from the group consisting of W and Y, and the substitution at position 44 is T;
(b) a polypeptide consisting of the sequence set forth in amino acids 19 through 134 of SEQ ID NO: 2, except for a single amino acid substitution at position 28, and a single amino acid substitution at position 44, wherein the substitution at position 28 is selected from the group consisting of W and Y, and the substitution at position 44 is T;
(c) a polypeptide consisting of the sequence set forth in amino acids 23 through 134 of SEQ ID NO: 2, except for a single amino acid substitution at position 28, and a single amino acid substitution at position 44, wherein the substitution at position 28 is selected from the group consisting of W and Y, and the substitution at position 44 is T;
(d) a polypeptide consisting of the sequence set forth in amino acids 25 through 134 of SEQ ID NO: 2, except for a single amino acid substitution at position 28, and a single amino acid substitution at position 44, wherein the substitution at position 28 is selected from the group consisting of W and Y, and the substitution at position 44 is T;
(e) a polypeptide having at least 80% sequence identity to any one of (a) through (d), except for a single amino acid substitution at position 28, and a single amino acid substitution at position 44, wherein the substitution at position 28 is selected from the group consisting of W and Y, and the substitution at position 44 is T, wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11.

### Claim 2

An isolated protein comprising a stabilized activin IIB receptor polypeptide, wherein said polypeptide is selected from the group consisting of:
(a) a polypeptide consisting of the sequence set forth in the group consisting of SEQ ID NO: 4, 6, 12 and 14;
(b) a polypeptide having at least 90% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11, and
(c) polypeptides having at least 95% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11.

### Claim 3 (depends on 2)

The protein of claim 2, wherein the polypeptide is connected to at least one heterologous protein.

### Claim 4 (depends on 3)

The protein of claim 3, wherein the heterologous polypeptide is an IgG Fc domain.

### Claim 5 (depends on 3)

The protein of claim 3, wherein the heterologous polypeptide is connected to the polypeptide by a linker sequence.

### Claim 6 (depends on 5)

The protein of claim 5, wherein the linker is selected from the group consisting of: SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49 and SEQ ID NO: 50.

### Claim 7 (depends on 4)

The protein of claim 4, wherein the protein comprises a polypeptide selected from the group consisting of:
(a) a polypeptide consisting of the sequence set forth in the group consisting of SEQ ID NO: 8, 10, 16 and 18;
(b) a polypeptide having at least 90% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11, and
(c) polypeptides having at least 95% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11.

### Claim 8 (depends on 2)

The protein of claim 2, wherein the amino acid residue at position 64 is alanine.

### Claim 9 (depends on 1)

An isolated nucleic acid molecule comprising a polynucleotide encoding the polypeptide of claim 1.

### Claim 10

An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide consisting of the sequence set forth in the group consisting of SEQ ID NO: 4, 6, 12, and 14;
(b) a polynucleotide encoding a polypeptide having at least 90% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44; and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11; and
(c) a polynucleotide encoding a polypeptide having at least 95% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11.

### Claim 11 (depends on 10)

The nucleic acid molecule of claim 10, wherein the polynucleotide has the sequence selected from the group consisting of SEQ ID NO: 3, 5, 11 and 13 or its complement.

### Claim 12 (depends on 10)

The nucleic acid molecule of claim 10, wherein the polynucleotide further comprises polynucleotides encoding at least one heterologous protein.

### Claim 13 (depends on 12)

The nucleic acid molecule of claim 12, comprising a polynucleotide selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide consisting of the sequence set forth in the group consisting of SEQ ID NO: 8, 10, 16, and 18;
(b) a polynucleotide encoding a polypeptide having at least 90% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11; and
(c) a polynucleotide encoding a polypeptide having at least 95% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11.

### Claim 14 (depends on 13)

The nucleic acid molecule of claim 13, wherein the polynucleotide has the sequence selected from the group consisting of SEQ ID NO: 7, 9, 15 and 17, or it complement.

### Claim 15 (depends on 10)

The nucleic acid molecule of claim 10, wherein the polynucleotide is operably linked to a transcriptional or translational regulatory sequence.

### Claim 16 (depends on 10)

A recombinant vector comprising the nucleic acid molecule of claim 10.

### Claim 17 (depends on 16)

A host cell comprising the recombinant vector of claim 16.

### Claim 18 (depends on 17)

The host cell of claim 17, wherein the host cell is a mammalian cell.

### Claim 19 (depends on 17)

A method of producing an svActRIIB protein comprising culturing the host cell of claim 17 under conditions promoting the expression of the protein, and recovering the protein.

### Claim 20 (depends on 2)

A pharmaceutical composition comprising an effective amount of the protein of claim 2 in admixture with a pharmaceutically acceptable carrier.

### Claim 21 (depends on 20)

A method of inhibiting myostatin activity or activin activity in a subject in need of such treatment comprising administering a therapeutically effective amount of the composition of claim 20 to the subject.

### Claim 22 (depends on 20)

A method of increasing lean muscle mass or increasing the ratio of lean muscle mass to fat mass in a subject in need of such treatment comprising administering a therapeutically effective amount of the composition of claim 20 to the subject.

### Claim 23 (depends on 20)

A method of treating a muscle-wasting disease or metabolic disorder in a subject in need of such treatment comprising administering a therapeutically effective amount of the composition of claim 20 to the subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein the muscle-wasting disease is selected from muscular dystrophy, amyotrophic lateral sclerosis, congestive obstructive pulmonary disease, chronic heart failure, cancer cachexia, AIDS, renal failure, uremia, rheumatoid arthritis, age-related sarcopenia, organ atrophy, carpal tunnel syndrome, androgen deprivation, burn injury, diabetes, and muscle-wasting due to prolonged bed rest, spinal chord injury, stroke, bone fracture, aging or exposure to micro-gravity.

### Claim 25 (depends on 23)

The method of claim 23, wherein the metabolic disorder is selected from diabetes, obesity, hyperglycemia, and bone loss.

### Claim 26 (depends on 20)

A method of treating a disease in which activin is overexpressed in a subject in need of such treatment comprising administering a therapeutically effective amount of the composition of claim 20 to said subject.

### Claim 27 (depends on 26)

The method of claim 26, wherein the disease is cancer.

### Claim 28 (depends on 16)

A method of treating a muscle wasting or metabolic or activin related disorder in a subject in need of such a treatment comprising administering the vector of claim 16 to the subject, wherein the vector is capable of directing expression of an svActRIIB polypeptide in the subject.
